Corient Private Wealth
AXSM icon

Corient Private Wealth’s Axsome Therapeutics AXSM Stock Holding History

Corient Private Wealth’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
5,156
+13
+0.3% +$2.82K ﹤0.01% 1670
2026
Q1 		$868K Buy
+5,143
New +$888K ﹤0.01% 1736
2025
Q1 		– Sell
-2,829
Closed -$239K – 2293
2024
Q4 		$239K Buy
+2,829
New +$260K ﹤0.01% 2017

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Corient Private Wealth's AXSM Position: Q2 2026 in Review

Corient Private Wealth increased its Axsome Therapeutics (AXSM) stake by 0.25% in Q2 2026, buying an estimated $2.82K and bringing the position to 5,156 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1670.

Corient Private Wealth first reported a position in AXSM in Q4 2024 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Corient Private Wealth held 5,156 shares of Axsome Therapeutics worth $1.26M as of Q2 2026.
  • Corient Private Wealth bought 13 Axsome Therapeutics shares in Q2 2026, an estimated $2.82K.
  • Axsome Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1670 holding.
  • Corient Private Wealth first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.